# Carboplatin-cyclophosphamide Combined With Atezolizumab

> **NCT02914470** · PHASE1 · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 12 (actual)

## Conditions studied

- Breast Cancer
- Cervix Cancer
- Ovarian Cancer
- Endometrial Cancer

## Interventions

- **DRUG:** carbplatin, cyclophophamide, atezolizumab

## Key facts

- **NCT ID:** NCT02914470
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2017-08
- **Final completion:** 2021-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02914470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02914470, "Carboplatin-cyclophosphamide Combined With Atezolizumab". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02914470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*